Cencora, Inc. COR

NYSE · Healthcare · Medical - Distribution

$339.09

Close on Fri, 20 Nov 2026 · market value $64.7B

What the price is betting on

Below its record

At $339, the price assumes revenue shrinks about 2.1% a year for five years, from $337B to about $303B by FY2031. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−2.1%
Analysts, next two years4.5%
Last 3 years8.8%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.6% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than COR? Check up to 5 of your stocks at once, free, no account.

0$200B$400B$600B$337B'23'24'25'26'27'28'29'30'31What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$448

Base

$501

Bull

$560

Today $339

  • Bear $448. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $501. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $560. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2027$330B$352B, on the path
  3. FY2028$323B$369B, on the path
  4. FY2029$316B$390B, on the path
  5. FY2030$310B$410B, on the path
  6. FY2031$303B$426B, on the path

Each year's revenue at −2.1% growth from $337B in FY2026.

At a glance

Healthcare · Medical - Distribution · listed on NYSE

Revenue, FY2026
$337B
Growth, 3 years a year
8.8%
Cash margin
1.2%
Net debt
$6.4B
Shares, 3-year change
−5.1%
Dividend yield
0.7%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.